The Ebola virus outbreak of fall 2014 was a wake-up call, says David Dausey, who is the dean of School of Health Professions and Public Health at Mercyhurst University. It showed that even the developed world isn’t prepared fully for an outbreak of infectious disease.
Companies are stepping up to improve health care’s preparedness for the next outbreak. From an investing perspective, the smart play is to go big, says Michael A. Robinson of Strategic Tech Investor.
He particularly likes Johnson & Johnson (NYSE: JNJ; Price: $108.30), because it has deep enough pockets that its stock won’t suffer if in-trial medications were deemed to be ineffective, unlike smaller companies that are developing vaccines. The stock has a mean analyst recommendation of “buy,” according to Zacks Investment Research.